NCT00041509View on ClinicalTrials.gov

ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST)

PHASE2CompletedINTERVENTIONAL

Enrollment

343

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

May 31, 2003

Study Completion Date

May 31, 2003

Conditions

Arthroplasty

Interventions

DRUG

SB-424323

500 mg, oral, BID for 28 days or 125 mg, oral, BID for 28 days

DRUG

Placebo

matching placebo, oral, BID for 28 days

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00041509 - ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST) | Biotech Hunter | Biotech Hunter